David K. Cole

TL;DR: Phage display is used to isolate and enhance a T-cell antigen receptor originating from a CTL line derived from an infected person and specific for the immunodominant HLA-A*02-restricted, HIVgag-specific peptide SLYNTVATL (SL9), which effectively controlled wild-type and mutant strains of HIV at effector-to-target ratios that could be achieved by T- cell therapy.

TL;DR: An update of the VDJdb database with a substantial increase in the number of T-cell receptor (TCR) sequences and their cognate antigens and a reduced set of high-quality TCR motifs that can be used for both training TCR specificity predictors and matching against TCRs of interest are reported.

TL;DR: The data provide information on the binding interplay between CD8 and the TCR and support a model of CTL activation in which the extent of coreceptor dependence is inversely correlated to TCR/pMHCI affinity.

TL;DR: A panel of soluble TCR molecules originating from human T cells that respond to naturally occurring disease epitopes and their cognate pMHCs is produced, providing experimental support for the notion that binding half-life is the principal kinetic feature controlling T cell activation.

TL;DR: Some of the ‘tricks’ that can be used to get the most out of pMHC multimers are discussed and the problems that arise are discussed because of the low affinity of TCR/pMHCII interactions and lack of ‘coreceptor help’.